• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ: REGN )

    838.20 -84.59 (-9.17%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Regeneron Pharmaceuticals

    < Previous 1 2
    ...
    7 8 9 10 11 12 13 14 15
    ...
    41 42 Next >
    $1000 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    14 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know
    Via Benzinga
    Price Over Earnings Overview: Regeneron Pharmaceuticals
    Via Benzinga
    It's Almost 2024: 3 Top Stocks to Buy Before the New Year
    You can pick these players up for a great price right now. 
    Via The Motley Fool
    (REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
    Via Benzinga
    11 Analysts Have This to Say About Regeneron Pharmaceuticals
    Via Benzinga
    If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
    Via Benzinga
    AI Meets Biotech: 3 Top Stocks Transforming Medical Science
    The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. 
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    3 Stocks to Buy Before 2024 That Can Set You Up For Life
    These stocks are still relatively cheap, but don't expect them to stay that way for long. 
    Via The Motley Fool
    Reasonable growth and debt and a high ROIC for REGENERON PHARMACEUTICALS (NASDAQ:REGN).
    Exploring REGENERON PHARMACEUTICALS (NASDAQ:REGN)'s quality characteristics. 
    Via Chartmill
    3 Gene-Editing Stocks With the Potential to Mint Millionaires
    Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. 
    Via InvestorPlace
    Exposures Product Safety
    Biotech Is Coming Back, Can The Run Last?
    The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
    Via Talk Markets
    Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    3 biotech powerhouses poised to thrive amid sector rebound
    If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. 
    Via MarketBeat
    Topics ETFs
    Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?
    Regeneron has been an excellent investment in recent years. Can that trend continue? 
    Via The Motley Fool
    Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise
    Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
    Via Investor's Business Daily
    You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
    The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
    Via The Motley Fool
    GOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places
    The company continues to buy back Alphabet stock in large quantities. As for its other equity investments, it ought to stick with the S&P 500. 
    Via InvestorPlace
    Topics Stocks
    Exposures US Equities
    $1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Biotech And Healthcare Portfolio Playbook For December 2023/24
    We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. 
    Via Talk Markets
    Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
    Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation. 
    Via Investor's Business Daily
    Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
    Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that... 
    Via Benzinga
    Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    9 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    < Previous 1 2
    ...
    7 8 9 10 11 12 13 14 15
    ...
    41 42 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.